Mason, L. http://orcid.org/0000-0001-9978-7349
Shic, F.
Falck-Ytter, T.
Chakrabarti, B.
Charman, T.
Loth, E.
Tillmann, J.
Banaschewski, T.
Baron-Cohen, S.
Bölte, S.
Buitelaar, J.
Durston, S.
Oranje, B.
Persico, A. M.
Beckmann, C.
Bougeron, T.
Dell’Acqua, F.
Ecker, C.
Moessnang, C.
Murphy, D.
Johnson, M. H.
Jones, E. J. H.
Ahmad, Jumana
Ambrosino, Sara
Baumeister, Sarah
Bours, Carsten
Brammer, Michael
Brandeis, Daniel
Brogna, Claudia
de Bruijn, Yvette
Chatham, Chris
Cornelissen, Ineke
Crawley, Daisy
Dumas, Guillaume
Faulkner, Jessica
Frouin, Vincent
Garcés, Pilar
Goyard, David
Ham, Lindsay
Hipp, Joerg
Holt, Rosemary
Lai, Meng-Chuan
D’ardhuy, Xavier Liogier
Lombardo, Michael V.
Lythgoe, David J.
Mandl, René
Marquand, Andre
Mennes, Maarten
Meyer-Lindenberg, Andreas
Bast, Nico
Oakley, Bethany
O’Dwyer, Laurence
Oldehinkel, Marianne
Pandina, Gahan
Ruggeri, Barbara
Ruigrok, Amber
Sabet, Jessica
Sacco, Roberto
Cáceres, Antonia San José
Simonoff, Emily
Spooren, Will
Toro, Roberto
Tost, Heike
Waldman, Jack
Williams, Steve C. R.
Wooldridge, Caroline
Zwiers, Marcel P.
,
Funding for this research was provided by:
innovative medicines initiative (115300, 777394)
medical research council (MR/K021389/1, MR/T003057/1)
Article History
Received: 2 July 2021
Accepted: 3 November 2021
First Online: 15 December 2021
Declarations
:
: The study was approved by the local ethical committees of participating centres, and written informed consent was obtained from all participants or their legal guardians (for participants < 18 years).
: Not applicable.
: FS consults for Roche, Janssen and BlackThorn Therapeutics. SB discloses that he has in the last 3 years acted as an author, consultant or lecturer for Medice and Roche. He receives royalties for text books and diagnostic tools from Hogrefe, Kohlhammer and UTB. JB has been in the past 3 years a consultant to/member of advisory board of/and/or speaker for Takeda/Shire, Roche, Medice, Angelini, Janssen and Servier. He is not an employee of any of these companies and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, royalties.